MedTrace Logo

HRYZ-T101 Injection for HPV18 Positive Solid Tumor

NCT05952947 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-02-02

No results posted yet for this study

Summary

A multicenter, open label, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 injection for HPV18 positive solid tumor. The study will investigate RP2D of HRYZ-T101 TCR-T cell injection.

Conditions

Interventions

BIOLOGICAL

HRYZ-T101 Injection

On day 1, the TCR-T cells will be administered intravenously.

DRUG

Fludarabine + Cyclophosphamide

Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days

Sponsors & Collaborators

  • HRYZ Biotech Co.

    lead INDUSTRY

Principal Investigators

  • Xiaohua Wu, Doctor · Fudan University

  • Jian Zhang, Doctor · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2027-12-31
Completion
2028-02-29

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05952947 on ClinicalTrials.gov